| Human Immunodeficiency Virus |
| Not yet recruiting | 2 | 124 | Europe | Pneumococcal polysaccharide conjugate vaccine, Pneumococcal Polysaccharide Vaccine, Suspension for injection in pre-filled syringe, Solution for injection | Cambridge University Hospital NHS Foundation Trust and University of Cambridge, Arthritis Research UK | Pneumococcal vaccine responses in ANCA associated vasculitis, Vasculitis, Diseases [C] - Immune System Diseases [C20] | | | | |
| Completed | 2 | 86 | NA | Doravirine, Tenofovir, Lamivudine - Blinded, MK-1439A, Doravirine, Tenofovir, Lamivudine - Open-Label, ATRIPLA^TM, Placebo to ATRIPLA™, Placebo to Doravirine, Tenofovir, Lamivudine | Merck Sharp & Dohme LLC | HIV-1, Central Nervous System | 08/18 | 02/24 | | |
2018-002125-30: A study to evaluate how safe MVA.HTI and ChAdOx1.HTI vaccines with vesatolimod are in participants with early treated HIV-1 infection. Un estudio para evaluar la seguridad de las vacunas MVA.HTI y ChAdOx1.HTI con vesatolimod en sujetos participantes con infección por VIH-1 tratados de forma precoz. |
|
|
| Not yet recruiting | 2 | 57 | Europe | MVA.HTI, ChAdOx1.HTI, Vesatolimod, MVA.HTI, ChAdOx1.HTI, GS-9620, Suspension for injection, Film-coated tablet | AELIX Therapeutics, AELIX Therapeutics | Human immunodeficiency virus type 1 Virus de inmunodeficiencia humana tipo 1, Human immunodeficiency virus (HIV) Virus de inmunodeficiencia humana (VIH), Diseases [C] - Virus Diseases [C02] | | | | |
NCT03639311: Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study |
|
|
| Completed | 2 | 97 | Canada, US | CAB LA, RPV LA, RPV, DTG | ViiV Healthcare, Janssen, LP | HIV Infections | 12/19 | 01/23 | | |
2019-004195-19: A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma viremia below 50 copies/mL under a current antiretroviral regimen |
|
|
| Not yet recruiting | 2 | 150 | Europe | Isentress, Pifeltro, J05AX08, J05AR24, Tablet, ISENTRESS, Pifeltro | Centre de Recherche et d’Etudes sur la Pathologie Tropicale et le Sida (CREPATS), Centre de Recherche et d’Etudes sur la Pathologie Tropical et le Sida (CREPATS), CREPATS, Centre de Recherche et d’Etudes sur la Pathologie Tropical et le Sida (CREPATS) | HIV disease, HIV disease, Diseases [C] - Virus Diseases [C02] | | | | |
| Not yet recruiting | 2 | 140 | Europe | Islatravir, MK-8507, MK-8591, MK-8507, Capsule, Tablet, Film-coated tablet, Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc | HIV-1 infection, HIV-1 infection, Diseases [C] - Virus Diseases [C02] | | | | |
| Active, not recruiting | 2 | 22 | Canada | Somatotropin (Human) | McGill University Health Centre/Research Institute of the McGill University Health Centre, EMD Serono | Human Immunodeficiency Virus, Growth Hormone Treatment | 03/21 | 12/24 | | |
NCT03536234 / 2017-004160-35: Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients |
|
|
| Recruiting | 2 | 52 | Europe | Triptorelin acetate depot | Immune System Regulation AB | HIV-1-infection | 08/21 | 12/21 | | |
CALIBRATE, NCT04143594: Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With Other Antiretroviral Agents in People Living With HIV |
|
|
| Completed | 2 | 183 | US, RoW | Oral Lenacapavir, GS-6207, F/TAF, Descovy®, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF, Biktarvy® | Gilead Sciences | HIV-1-infection | 09/21 | 09/23 | | |
| Completed | 2 | 42 | Europe, US, RoW | DOR/ISL, MK-8591A, Doravirine/islatravir | Merck Sharp & Dohme LLC | HIV-1 Infection | 12/21 | 01/23 | | |
2017-000437-32: Dose Ranging Trial of MK-8591 Given in Combination with Doravirine (DOR) and Lamivudine (3TC) |
|
|
| Not yet recruiting | 2 | 120 | Europe | MK-8591, Doravirine, Doravirine/Lamivudine/Tenofovir disoproxil fumarate, Epivir, MK-8591A, MK-8591, MK-1439, MK-1439A, MK-8591A, Capsule, Film-coated tablet, Epivir | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | HIV-1 infection, HIV-1 infection, Diseases [C] - Virus Diseases [C02] | | | | |
NCT05112848: A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19) |
|
|
| Completed | 2 | 384 | RoW | NVX-CoV2373, Monovalent SARS-CoV-2 rS vaccine premixed with Matrix-M adjuvant | Novavax | SARS-CoV-2 Infection | 05/22 | 11/22 | | |
| Active, not recruiting | 2 | 28 | US | PRO 140 350mg weekly SQ injection., PRO 140 | CytoDyn, Inc. | HIV, Human Immunodeficiency Virus | 06/22 | 08/22 | | |
NCT04819347: Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection |
|
|
| Not yet recruiting | 2 | 24 | RoW | Albuvirtide, ABT, 3BNC117 | Frontier Biotechnologies Inc. | HIV/AIDS | 06/22 | 12/22 | | |
2021-001288-26: Safety, tolerance and antiretroviral activity of dasatinib: a pilot clinical trial in patients with recent HIV-1 infection Seguridad, tolerancia y actividad antirretroviral de dasatinib: estudio clínico piloto en pacientes con infección reciente por el VIH-1 |
|
|
| Not yet recruiting | 2 | 24 | Europe | Capsule, Dasatinib | IDIBAPS, Instituto de Salud Carlos III | Recent HIV-1 infection Infección reciente por VIH, Recent HIV-1 infection Infección reciente por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
| Terminated | 2 | 161 | Europe, Canada, US, RoW | GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir, Placebo | ViiV Healthcare | HIV Infections | 09/22 | 05/23 | | |
NCT04871113: A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults |
|
|
| Completed | 2 | 63 | Canada, US, RoW | GSK3810109A | ViiV Healthcare | HIV Infections | 10/22 | 09/23 | | |
NCT04560569: Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection |
|
|
| Recruiting | 2 | 20 | US | Albuvirtide, ABT, 3BNC117 Antibody, 3BNC117 | Frontier Biotechnologies Inc. | HIV/AIDS | 11/22 | 12/22 | | |
| Terminated | 2 | 85 | Europe, Canada, US, RoW | GSK3640254, Dolutegravir, Lamivudine capsules, Lamivudine tablets | ViiV Healthcare, Syneos Health | HIV Infections | 11/22 | 05/23 | | |
NCT03719664: Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects |
|
|
| Recruiting | 2 | 80 | US | Albuvirtide, Fusion inhibitor, 3BNC117, Monoclonal antibody, Baseline ART, ART | Frontier Biotechnologies Inc. | HIV-1-infection | 12/22 | 12/22 | | |
NCT05022212: Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition |
|
|
| Completed | 2 | 45 | RoW | LACTIN-V, Lactobacillus crispatus CTV-05, Placebo | University of California, San Francisco, University of KwaZulu, Harvard University, Aurum Institute, Health Systems Trust, Osel, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Bacterial Vaginosis, HIV Infections | 03/23 | 03/23 | | |
NCT05005078: A 16-Week Study of Pirenzepine or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy in Patients With HIV |
|
|
| Completed | 2 | 16 | US | WST-057, Placebo | WinSanTor, Inc | HIV Associated Polyneuropathy | 01/23 | 01/23 | | |
NCT02741128: Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults |
|
|
| Completed | 2 | 133 | RoW | CYD Dengue Vaccine, Placebo (NaCl 0.9%) vaccine group | Sanofi Pasteur, a Sanofi Company | Dengue Fever, Dengue Hemorrhagic Fever, Human Immunodeficiency Virus | 01/23 | 01/23 | | |
NCT05056974: A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs |
|
|
| Completed | 2 | 11 | RoW | UB-421, chidamide | United BioPharma | HIV-1 Infection | 02/23 | 02/23 | | |
NCT04012931 / 2018-004301-32: A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed |
|
|
| Completed | 2 | 26 | Europe, RoW | Rilpivirine, TMC278, ARV Background Regimen | Janssen Research & Development, LLC, Janssen Sciences Ireland Unlimited Company, Janssen Sciences Ireland UC | HIV | 02/23 | 02/23 | | |
| Active, not recruiting | 2 | 250 | Canada | V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine, Saline | Cecile Tremblay, Merck Sharp & Dohme LLC, International Development Research Centre, Canada, Dalhousie University, Université de Montréal, Coalition for Epidemic Preparedness Innovations | Ebola | 03/24 | 02/25 | | |
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection |
|
|
| Completed | 2 | 45 | US, RoW | Glecaprevir/Pibrentasvir (G/P), Ribavirin (RBV) | AIDS Clinical Trials Group, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis C Infection, HIV Infection | 05/23 | 08/23 | | |
2023-000061-14: Safety and Impact of Dasatinib on the amount of HIV and Inflammation in People with Human Immunodeficiency Virus under Antiretroviral Treatment Seguridad e impacto de Dasatinib sobre la cantidad de virus VIH y la inflamación en personas con Virus de inmunodeficiencia Humana que siguen tratamiento antirretroviral |
|
|
| Not yet recruiting | 2 | 60 | Europe | dasatinib, 1381Q, Tablet, Sprycel, Dasatinib-Teva | Institut de Recerca Germans Trias i Pujol, Instituto de Salud Carlos III | Human immunodeficiency virus (HIV) Virus de la Inmunodeficiencia humana (VIH), Human immunodeficiency virus (HIV) Virus de la Inmunodeficiencia humana (VIH), Diseases [C] - Virus Diseases [C02] | | | | |
VOLVER, NCT04880785: Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine |
|
|
| Completed | 2 | 121 | Europe | Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato] | Fundacion SEIMC-GESIDA, ViiV Healthcare | HIV Infections | 06/23 | 04/24 | | |
2022-000829-24: Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children, 6 to less than 12 years of age, Living with HIV-1 |
|
|
| Not yet recruiting | 2 | 20 | US | JULUCA, J05AR21, Tablet, (GSK3365791 (GSK1349572+GSK1329758); JULUCA (Dolutegravir 50 mg and Rilpivirine 25 mg Fixed Dose Combination Tablet) | ViiV Healthcare UK Limited, ViiV Healthcare, Janssen Research and Development | Virologically Suppressed Children, 6 to less than 12 years of age, Living with HIV-1, HIV-1, Diseases [C] - Virus Diseases [C02] | | | | |
NCT03386578: Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum |
|
|
| Completed | 2 | 390 | RoW | Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF), Truvada, Behavioral HIV risk reduction package | National Institute of Allergy and Infectious Diseases (NIAID), Gilead Sciences | HIV Infections | 10/23 | 02/24 | | |
| Active, not recruiting | 2 | 330 | RoW | emtricitabine/tenofovir alafenamide, Descovy, Emtricitabine / Tenofovir Disoproxil Oral Tablet, Truvada | Eastern Virginia Medical School, CONRAD, FHI 360, United States Agency for International Development (USAID), Gilead Sciences | Acceptability of Health Care, Adherence, Medication | 12/23 | 04/24 | | |
NCT05330143: Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV |
|
|
| Recruiting | 2 | 30 | RoW | ASC22 1mg/kg, KN035, ASC22 2.5mg/kg, Antiretroviral Therapy, Placebo | Ascletis Pharmaceuticals Co., Ltd. | HIV-1-infection, HIV Infections, PD-L1 Gene Mutation | 12/23 | 12/23 | | |
MK-8591-013, NCT04564547: Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [] |
|
|
| Active, not recruiting | 2 | 161 | Europe, US | Islatravir, MK-8591, Ulonivirine, MK-8507, BIC/FTC/TAF, BIKTARVY®, Placebo to ISL, Placebo to Ulonivirine, Placebo to BIC/FTC/TAF | Merck Sharp & Dohme LLC | HIV-1 Infection | 12/24 | 12/24 | | |
NCT05052996: Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV |
|
|
| Active, not recruiting | 2 | 142 | US | ISL, LEN, GS-6207, B/F/TAF, Biktarvy® | Gilead Sciences, Merck Sharp & Dohme LLC | HIV-1 Infection | 12/23 | 11/27 | | |
| Recruiting | 2 | 48 | US | Artesunate ointment, Artesunic acid, Dihydroartemisinin (DHA), Artemisinin, Placebo, placebo ointment | Frantz Viral Therapeutics, LLC, Laser Surgery Care, LLC, Anal Dysplasia Clinic MidWest | Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection | 12/25 | 12/25 | | |
NCT03201939: Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria |
|
|
| Suspended | 2 | 280 | RoW | Lisinopril, Intervention arm, Placebo Oral Tablet, Control arm | Vanderbilt University Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Aminu Kano Teaching Hospital, SAIC-Frederick, Inc., Brigham and Women's Hospital | HIV/AIDS, Albuminuria, Kidney Diseases, Genetic Predisposition | 02/25 | 02/25 | | |
NCT06214052: VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1 |
|
|
| Recruiting | 2 | 28 | Europe, Canada, US, RoW | VH4524184, Placebo | ViiV Healthcare, GlaxoSmithKline | HIV Infections | 09/24 | 09/24 | | |
| Active, not recruiting | 2 | 17 | US | Artesunate, Artesunic acid, dihydroartemisinin (DHA), artemisinin, Placebo | Frantz Viral Therapeutics, LLC, Amarex CRO, University of California, San Francisco, Anal Dysplasia Clinic MidWest, Laser Surgery Care | Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection, Anal Dysplasia, HPV Disease | 12/24 | 12/24 | | |
NCT03164447: UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients |
|
|
| Not yet recruiting | 2 | 10 | NA | UB-421, Optimized background therapy (OBT) | United BioPharma | HIV-1 Infection | 03/24 | 05/24 | | |
DOR, NCT06034938: /TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road) |
|
|
| Not yet recruiting | 2 | 32 | Europe | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO], Delstrigo | University Hospital, Caen, Merck Sharp & Dohme LLC | Hiv | 04/24 | 05/25 | | |
NCT06306196: Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children |
|
|
| Not yet recruiting | 2 | 860 | NA | Hecolin® Recombinant Hepatitis E Vaccine, Isotonic Sodium Chloride injection | International Vaccine Institute, Xiamen Innovax Biotech Co., Ltd, Bill and Melinda Gates Foundation | Hepatitis E Virus Infection | 01/26 | 01/26 | | |
CINNAMON, NCT06039579: Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults |
|
|
| Active, not recruiting | 2 | 43 | Europe, Canada, US, RoW | VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo | ViiV Healthcare | HIV Infections | 06/24 | 06/24 | | |
NCT05869643: A Clinical Trial of STP0404 in Treatment-Naïve Adults With HIV-1 Infection |
|
|
| Recruiting | 2 | 36 | US | Low-dose STP0404 (Pirmitegravir), Medium-dose STP0404 (Pirmitegravir), High-dose STP0404 (Pirmitegravir), Placebo | ST Pharm Co., Ltd. | HIV-1-infection | 10/24 | 11/24 | | |
NCT03739996: Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 |
|
|
| Completed | 2 | 75 | US | Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA), VRC07-523LS, VRC-HIVMAB075-00-AB, Standard of Care (SOC) Oral ART | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 04/24 | 04/24 | | |
NCT06411223: Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs |
|
|
| Not yet recruiting | 2 | 50 | US | Collaborative drug therapy management model, CDTM+, Cabotegravir/Rilpivirine, CAB/RPV LA | Yale University, ViiV Healthcare | Hiv | 05/25 | 05/25 | | |
NCT06061536: Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients. |
|
|
| Recruiting | 2 | 64 | RoW | Lipovirtide 10mg, 3TC, TDF, Lipovirtide 40mg, Lipovirtide 60mg, DTG | Shanxi Kangbao Biological Product Co., Ltd., Institute of Pathogen Biology, Chinese Academy of Medical Sciences | HIV | 06/24 | 10/24 | | |
NCT06061081: A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1 |
|
|
| Not yet recruiting | 2 | 26 | Europe, US, RoW | VH3739937, Placebo | ViiV Healthcare | HIV Infections | 06/24 | 06/24 | | |
NCT05630872: Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis |
|
|
| Recruiting | 2 | 30 | RoW | Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC, DTG 50 mg orally QD plus TDF/3TC, 2HPZM, 2HPM | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare, Mylan Inc. | HIV-associated Tuberculosis | 02/25 | 09/25 | | |
NCT04404049: The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients |
|
|
| Not yet recruiting | 2 | 39 | NA | UB-421(25 mg/kg) Q2W, UB-421(25 mg/kg) Q4W | UBP Greater China (Shanghai) Co., Ltd | HIV-1-infection | 06/24 | 06/25 | | |
| Not yet recruiting | 2 | 110 | US | ISS-SBDOH arm | University of California, Los Angeles, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, EtectRX, Inc., National Institute on Minority Health and Health Disparities (NIMHD) | HIV/AIDS, Medication Adherence, Social Determinants of Health (SDOH) | 12/27 | 12/27 | | |
NCT05835479: Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults |
|
|
| Recruiting | 2 | 50 | RoW | Co-Trimoxazole, Rezafungin Acetate / Co Trimoxazole | Mundipharma Research Limited | Pneumocystis Pneumonia | 10/24 | 12/24 | | |
PREPARE, NCT05832502: Clinical Trial Investigating the Safety and Immunogenicity of GBS6 in Pregnant Women With and Without HIV |
|
|
| Active, not recruiting | 2 | 300 | RoW | GBS6, Hexavalent anti capsular polysaccharide (CPS) / cross reactive material 197 glycoconjugate, Placebo | St George's, University of London, MU-JHU CARE, Pfizer | Group B Streptococcal Infection | 09/25 | 09/25 | | |
EMBRACE, NCT05996471: A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) |
|
|
| Active, not recruiting | 2 | 99 | US | VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20 | ViiV Healthcare | HIV Infections | 11/24 | 05/26 | | |
NCT05281510: Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women |
|
|
| Active, not recruiting | 2 | 21 | RoW | Vesatolimod, GS-9620, VRC07523LS, CAP256V2LS | Gilead Sciences | HIV-1-infection | 03/25 | 03/25 | | |
HVTN605A5421, NCT05947890: Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa |
|
|
| Recruiting | 2 | 276 | RoW | MTBVAC, BCG | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), Biofabri, S.L | HIV I Infection, Tuberculosis | 11/24 | 11/24 | | |
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV |
|
|
| Active, not recruiting | 2 | 110 | US | CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg | National Institute of Allergy and Infectious Diseases (NIAID), AbbVie | HIV-1-infection | 07/24 | 07/24 | | |
NCT03601806: Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection |
|
|
| Active, not recruiting | 2 | 26 | RoW | Laboratory Biomarker Analysis, Pomalidomide, 4-Amino thalidomide, Actimid, CC-4047, Imnovid, Pomalyst | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas, Montefiore Medical Center, University of Stellenbosch, Weill Medical College of Cornell University, University of California, Los Angeles | Human Immunodeficiency Virus 1 Positive, Skin Kaposi Sarcoma | 11/24 | 01/26 | | |
| Recruiting | 2 | 160 | US | Saroglitazar Magnesium 4 mg, Placebo | Zydus Therapeutics Inc. | Nonalcoholic Steatohepatitis | 02/25 | 03/25 | | |
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. |
|
|
| Completed | 2 | 44 | US | Letermovir 240 MG Oral Tablet, PREVYMIS, Letermovir 480 MG Oral Tablet, Combination ART | National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC | HIV Infections, Cytomegalovirus, CMV | 11/23 | 11/23 | | |
NCT06045507: Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007) |
|
|
| Active, not recruiting | 2 | 350 | US, RoW | MK-8527, Placebo to MK-8527 | Merck Sharp & Dohme LLC | HIV, HIV Pre-exposure Prophylaxis | 12/24 | 12/24 | | |
NCT05729568: A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection |
|
|
| Active, not recruiting | 2 | 83 | Canada, US, RoW | Teropavimab, GS-5423, Zinlirvimab, GS-2872, Lenacapavir Tablet, GS-6207, Lenacapavir Injection, Antiretroviral Therapy | Gilead Sciences | HIV Infections | 07/24 | 12/29 | | |
NCT06032546: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 |
|
|
| Recruiting | 2 | 140 | Europe, Canada, Japan, US, RoW | Budigalimab, ABBV-181, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382 | AbbVie | Human Immuno-deficiency Virus (HIV) Disease | 04/25 | 10/26 | | |
MK-8591-043, NCT05115838: Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection |
|
|
| Withdrawn | 2 | 175 | NA | Islatravir, MK-8591, Placebo | Merck Sharp & Dohme LLC | Human Immunodeficiency Virus, HIV | 10/25 | 10/25 | | |
NCT03947775: HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL |
|
|
| Not yet recruiting | 2 | 228 | Canada | 9-valent HPV vaccination, Gardasil-9 | University Health Network, Toronto, Merck Sharp & Dohme LLC | Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus | 03/26 | 05/26 | | |
NCT02437851: Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection |
|
|
| Active, not recruiting | 2 | 16 | US | Therapeutic Conventional Surgery | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, AIDS and Cancer Specimen Resource, University of Arkansas | Anal Squamous Cell Carcinoma, HIV Infection, Stage 0 Anal Canal Cancer, Stage I Anal Canal Cancer | 03/26 | 03/26 | | |
NCT04985890: A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir |
|
|
| Not yet recruiting | 2 | 20 | NA | UB-421, UB-421+chidamide | UBP Greater China (Shanghai) Co., Ltd | HIV-1-infection | 12/26 | 12/27 | | |
RHIVIERA-02, NCT05300035: Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control |
|
|
| Recruiting | 2 | 69 | Europe | Recombinant human monoclonal antibody (bNAbs), 10-1074-LS and 3BNC117-LS, Placebo, Saline solution | ANRS, Emerging Infectious Diseases, Rockefeller University, Institut Pasteur | HIV/AIDS and Infections | 12/26 | 12/28 | | |
PURPOSE 3, NCT06101329: Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) |
|
|
| Recruiting | 2 | 250 | US | Lenacapavir Tablet, GS-6207, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF), Truvada® | Gilead Sciences, HIV Prevention Trials Network | Pre-Exposure Prophylaxis of HIV Infection | 01/28 | 01/28 | | |
PURPOSE-4, NCT06101342: Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) |
|
|
| Recruiting | 2 | 250 | US | Lenacapavir Injection, GS-6207, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Truvada® | Gilead Sciences, HIV Prevention Trials Network, National Institute on Drug Abuse (NIDA), National Institute of Allergy and Infectious Diseases (NIAID) | Pre-Exposure Prophylaxis of HIV Infection | 07/27 | 07/27 | | |
| Recruiting | 2 | 120 | US | Placebo, Pregnenolone, Neuroactive steroid | Massachusetts General Hospital, National Institute of Mental Health (NIMH), Institute for Medical Research, Inc. | Major Depressive Disorder, Anxiety Depression, HIV | 06/27 | 01/28 | | |
| Recruiting | 2 | 84 | US, RoW | Doravirine, MK-1439, 2 NRTIs | Merck Sharp & Dohme LLC | Human Immunodeficiency Virus (HIV) Infection | 03/28 | 04/34 | | |
NCT03603808: VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions |
|
|
| Active, not recruiting | 2 | 80 | US | Electroporation, electroporation therapy, EPT, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, VGX-3100, Laboratory Biomarker Analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, Inovio Pharmaceuticals | Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive | 09/29 | 09/29 | | |
NCT02494986 / 2014-002471-28: A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies |
|
|
| Active, not recruiting | 2 | 48 | Europe, RoW | Rilpivirine, TMC278, R278474 | Janssen Sciences Ireland UC | Human Immunodeficiency Virus Type 1 | 12/30 | 12/31 | | |
2005-001019-23: A double blind, phase I/II, randomized, single and repeat dose, dose escalation study of the antibody BI-201 directed against Tat, given IV, versus Placebo in asymptomatic HIV-1 patients. |
|
|
| Ongoing | 1/2 | 45 | Europe | BI-201, BI-201, | BioInvent International AB | HIV-1 (asymptomatic patients) | | | | |
2015-001023-23: A Phase I clinical trial to assess the safety and immunogenicity of HIV DNA immunisations administered via the Intramuscular and Intradermal methods with and without electroporation followed by boosting with recombinant HIV protein in healthy male and female volunteers |
|
|
| Not yet recruiting | 1/2 | 24 | Europe | DNA-C CN54ENV, CN54gp140, Solution for injection | Imperial College London, European Commission | HIV prophylaxis, Prevention of HIV infection, Diseases [C] - Virus Diseases [C02] | | | | |
2019-003102-26: Therapeutic vaccination: Phase I / II clinical study on patients randomized blinded to the experimental vaccine or placebo regimen. we want to evaluate the safety and the immunogenicity of a vaccine that includes a first administration of the ChAdOx1.tHIVconsvX product and a second one with MVA.tHIVconsvX in HIV-1 positive adults treated early and able to control the infection for a long time. Vaccinazione terapeutica: Studio clinico di fase I/II su pazienti randomizzati in cieco al regime con vaccino sperimentale o al placebo. si vuole valutare la sicurezza e l'immunogenicità di un vaccino che comprende una prima somministrazione del prodotto ChAdOx1.tHIVconsvX e una seconda con MVA.tHIVconsvX in adulti HIV-1 positivi trattati precocemente e in grado di controllare per lungo tempo l’infezione. |
|
|
| Not yet recruiting | 1/2 | 33 | Europe | ChAdOx1.tHIVconsv1, MVA.tHIVconsv3, MVA.tHIVconsv4, [C1], [M3], [M4], Solution for injection | OSPEDALE SAN RAFFAELE, Ministero della Salute - Ricerca Finalizzata RF-GR-2018-12367076, European AIDS Vaccine Initiative 2020 - Horizon 2020 (EAVI2020) | HIV infection INFEZIONE DA HIV, HIV infection INFEZIONE DA virus HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2020-001029-30: Use of Fostemsavir in HIV-1 infected children and adolescents with Multi Drug-Resistant virus Uso de fostemsavir en niños y adolescentes infectados por el VIH-1 con virus multirresistente |
|
|
| Ongoing | 1/2 | 60 | Europe | Fostemsavir, BMS-663068-03/GSK3684934A, not applicable, Tablet | Fondazione Penta ONLUS, ViiV Healthcare | HIV-1 infection in children and adolescents with Multi Drug-Resistant virus Infección por VIH-1 en niños y adolescentes con virus multirresistente, HIV-1 infection in children and adolescents who are failing their current combination antiretroviral therapy and have dual- or triple-class antiretroviral resistance Infección por VIH-1 en niños y adolescentes que están fracasando con su terapia antirretroviral combinada actual y tienen resistencia a los antirretrovirales de clase doble o triple., Diseases [C] - Virus Diseases [C02] | | | | |
2021-002008-11: Phase 1/2 study of IMC-M113V in virologically suppressed chronic HIV infection Estudio en fase I/II de IMC-M113V sobre la infección crónica por el VIH con supresión vírica |
|
|
| Ongoing | 1/2 | 53 | Europe | IMC-M113V, IMC-M113V, Concentrate for solution for infusion | Immunocore Limited, Immunocore Limited | Chronic HIV infection Infección crónica por el (VIH), HIV infection Infección (VIH), Diseases [C] - Virus Diseases [C02] | | | | |
ACTIVATE, NCT02471430: Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy |
|
|
| Completed | 1/2 | 17 | US | Panobinostat, Farydak, LBH589, Pegylated Interferon-alpha2a, Pegasys | Massachusetts General Hospital, Novartis, Genentech, Inc. | HIV Infection | 08/22 | 12/23 | | |
2022-001677-31: Promoting cell death of HIV-infected cells and reducing the size of the HIV reservoir: An investigator-initiated phase I/IIb clinical trial in people living with HIV on antiretroviral therapy (The AMBER Study) |
|
|
| Ongoing | 1/2 | 27 | Europe | Tablet, Venetoclax | Aarhus University Hospital, The Independent Research Fund Denmark, Vilhelm Pedersen og Hustrus Mindelegat, The Melbourne HIV Cure Consortium, The Australian National Health and Medical Research Council (NHMRC), Walter and Eliza Hall Institute of Medical Research | HIV-1 infection, HIV-1 infection, Diseases [C] - Immune System Diseases [C20] | | | | |
MOCHA, NCT03497676: More Options for Children and Adolescents (): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents |
|
|
| Active, not recruiting | 1/2 | 168 | US, RoW | Oral Cabotegravir (CAB), Oral Rilpivirine (RPV), Edurant, Long-Acting Injectable Cabotegravir (CAB LA), Long-Acting Injectable Rilpivirine (RPV LA), Combination Antiretroviral Therapy (cART) | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 02/23 | 06/25 | | |
NCT05041699: PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel |
|
|
| Recruiting | 1/2 | 40 | US | IPM Ring-105, IPM Ring-106 | International Partnership for Microbicides, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH) | Pharmacokinetics, Safety Issues, Bleeding | 08/24 | 12/24 | | |
IPCAVD-012, NCT02935686: A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults |
|
|
| Completed | 1/2 | 155 | US, RoW | Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant, Placebo, gp140 HIV Bivalent Vaccine | Janssen Vaccines & Prevention B.V. | Healthy | 11/23 | 11/23 | | |
NCT05275998: TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals |
|
|
| Recruiting | 1/2 | 90 | US | TMB-365/TMB-380, TMB-380 is also known as VRC07-523-LS | TaiMed Biologics Inc. | HIV-1-infection | 04/24 | 07/24 | | |
NCT03141060: Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB |
|
|
| Recruiting | 1/2 | 48 | RoW | Delamanid, DLM, Optimized multidrug background regimen (OBR) for children with MDR-TB | National Institute of Allergy and Infectious Diseases (NIAID), Otsuka Pharmaceutical Development & Commercialization, Inc. | Tuberculosis, HIV Infections | 02/25 | 07/26 | | |
NCT04648280: Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance |
|
|
| Recruiting | 1/2 | 60 | Europe, US, RoW | Fostemsavir | PENTA Foundation, ViiV Healthcare, PHPT Foundation, Hospital Universitario 12 de Octubre, Cromsource | HIV Infections With Multi Drug Resistant Virus | 06/25 | 06/28 | | |
| Not yet recruiting | 1/2 | 21 | NA | EB103 | Estrella Biopharma, Inc., Eureka Therapeutics Inc. | B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, HIV Associated Lymphoma, CNS Lymphoma, High-grade B-cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma | 12/26 | 12/27 | | |
NCT03730181: Tuberculosis Clinical Trials Consortium Study 35 |
|
|
| Recruiting | 1/2 | 72 | RoW | Rifapentine, Isoniazid | Centers for Disease Control and Prevention, University of Stellenbosch, Johns Hopkins University, Sanofi, University of Cape Town, Chris Hani Baragwanath Academic Hospital, Washington D.C. Veterans Affairs Medical Center | Latent Tuberculosis | 07/24 | 12/24 | | |
NCT05547464: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers |
|
|
| Recruiting | 1/2 | 732 | RoW | BNT164a1, BNT164b1, Placebo | BioNTech SE | Tuberculosis | 03/26 | 02/27 | | |
NCT04357821: Combinatorial Therapy to Induce an HIV Remission |
|
|
| Active, not recruiting | 1/2 | 11 | US | Combination Intervention | University of California, San Francisco, amfAR, The Foundation for AIDS Research, International AIDS Vaccine Initiative, Ichor Medical Systems Incorporated, National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, Mologen AG, GeoVax, Inc. | HIV/AIDS | 12/24 | 12/25 | | |
| Recruiting | 1/2 | 20 | US | Dolutegravir/Rilpivirine FDC, JULUCA | ViiV Healthcare, Janssen Research & Development, LLC | HIV Infections | 07/25 | 06/27 | | |
NCT05939167: Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage |
|
|
| Recruiting | 1/2 | 150 | RoW | mesenchymal stem cell, umbilical cord derived MSCs, saline | Cell Energy Life Sciences Group Co. LTD, Beijing 302 Hospital, Shenzhen Third People's Hospital, Fifth Hospital of Shijiazhuang City, Beijing YouAn Hospital | AIDS | 07/25 | 07/26 | | |
NCT04983030: Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults |
|
|
| Recruiting | 1/2 | 36 | US | Ad26.Mos4.HIV, MVA-BN-HIV, PGT121, PGDM1400, VRC07-523LS | Boris Juelg, MD PhD, Janssen Pharmaceuticals, Harvard School of Public Health (HSPH), Orlando Immunology Center, The University of Texas Health Science Center, Houston, National Institute of Allergy and Infectious Diseases (NIAID) | HIV, Acquired Immunodeficiency Syndrome, Immunologic Deficiency Syndrome, Acquired, Sexually Transmitted Diseases, Viral, Retroviridae Infections | 03/26 | 04/26 | | |
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1 |
|
|
| Recruiting | 1/2 | 45 | US, RoW | ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, GS-2872, 10-1074-LS, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences | HIV-1-infection | 04/26 | 04/26 | | |
NCT04223804: A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1 |
|
|
| Completed | 1b | 41 | Canada, US, RoW | ABBV-181, Budigalimab, Placebo | AbbVie | Human Immunodeficiency Virus (HIV), HIV Infection, HIV-1 | 02/23 | 02/23 | | |
NCT04811040: Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection |
|
|
| Completed | 1b | 32 | US | Oral Lenacapavir, GS-6207, Subcutaneous Lenacapavir, Teropavimab, 3BNC117-LS, GS-5423, Zinlirvimab, 10-1074-LS, GS-2872 | Gilead Sciences | HIV-1 Infection | 04/23 | 10/23 | | |
NCT04725877: VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers |
|
|
| Completed | 1a | 27 | US | VIR-1111, Placebo | Vir Biotechnology, Inc., Bill and Melinda Gates Foundation | HIV I Infection | 12/22 | 12/22 | | |
NCT01215006: A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects |
|
|
| Active, not recruiting | 1 | 48 | US | GSK1265744 injectable suspension, Placebo to match injectable suspension | GlaxoSmithKline, ViiV Healthcare | Infections, Human Immunodeficiency Virus and Herpesviridae, HIV Infection | 05/12 | 05/12 | | |
NCT02658227: Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women |
|
|
| Recruiting | 1 | 16 | US | Dapivirine, Dapivirine Vaginal Ring | International Partnership for Microbicides, Inc. | HIV Infections | 08/17 | 08/17 | | |